Bio-Path Holdings Reports Second Quarter 2020 Financial Results

HOUSTON, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilizea?? liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the second quarter ended June 30, 2020 and provided an update on recent corporate developments.
a??Despite the challenges from the COVID-19 pandemic, we were able to continue to make significant progress across our clinical development pipeline. Most importantly, as recently announced, we dosed the first patient in Stage 2 of our Phase 2 trial of prexigebersen as a combination treatment for patients suffering with acute myeloid leukemia (AML),a?? said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. a??We believe that this unique clinical trial design offers multiple potential paths to registration. We are encouraged by earlier safety and efficacy data that prexigebersen in combination with latest standard of care should significantly enhance patient outcomes in AML patients who otherwise have limited treatment options.a??a??As we look to the balance of the year, we will continue to advance our studies for prexigebersen and BP-1002. We look forward to initiating a Phase 1 study of prexigebersen for the treatment of solid tumors by year end and remain steadfast in our goal to bring these potentially lifesaving therapies to patients in need,a?? continued Mr. Nielsen.Recent Corporate Highlights

Announced First Patient Dosed in Amended Stage 2 of the Phase 2 Clinical Trial Evaluating Prexigebersen in Acute Myeloid Leukemia. On August 13, 2020, Bio-Path announced the enrollment and dosing of the first patient in the amended Stage 2 of the Phase 2 clinical study of prexigebersen (BP1001), a liposomal Grb2 antisense, for the treatment of AML in combination with frontline therapy decitabine and venetoclax.A 

Presented at the 2020 American Society of Clinical Oncology Annual Meeting. In May, Bio-Path presented a virtual poster presentation at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting. Dr. Maro Ohanian, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, discussed the Phase 2 study design of BP1001 (liposomal Grb2 antisense), Bio-Patha??s lead drug candidate, in combination with decitabine as a potential treatment for patients diagnosed with AML or high-risk myelodysplastic syndrome.A 

Financial Results for the Second Quarter Ended June 30, 2020
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Сентябрь 2020    »